Deal Committee Presentation Guide

Section 1

What Deal Committees Actually Evaluate

Deal committees — whether at large pharma, mid-cap biotech, or PE/VC firms — evaluate five areas when reviewing a proposed transaction. Each area must be addressed with data, not assertions. The strength of your presentation determines whether the committee approves, requests revisions, or rejects.

1. Comparable Transactions

Comparables are the foundation of every deal committee presentation. The committee needs to see where the proposed deal terms sit relative to recent market precedents. Without comparables, every number is an assertion — with comparables, every number is a data point. The quality of your comparables determines the committee's confidence in your proposed terms.

2. Risk-Adjusted Valuation

The committee needs an rNPV or Monte Carlo valuation that translates clinical probability, market assumptions, and deal economics into a risk-adjusted return. Single-point valuations are insufficient — committees want to see how sensitive the valuation is to key assumptions and what the downside scenario looks like.

3. Competitive Landscape

Every deal exists in competitive context. The committee will ask: what happens if 2-3 competitors reach market before this asset? What if a superior modality emerges? Competitive analysis must be current (updated within 30 days) and honest about risks. See our modality comparison benchmarks for competitive context.

4. Strategic Rationale

Why this deal, why now, why this partner? Strategic rationale connects the deal to the company's broader pipeline strategy, revenue goals, and competitive positioning. The strongest rationale addresses a specific pipeline gap or strategic need that has board-level visibility.

5. Negotiation Parameters

The committee must approve not just the deal concept but the negotiation authority. This means clear walk-away points, trade-off frameworks, and competitive leverage positions. BD teams that go to committee without pre-approved negotiation parameters lose time going back for re-approval on every term change.

Section 2

How to Present Comparable Deals

Comparable deals are the most scrutinized element of any deal committee presentation. A well-constructed comp set builds confidence; a poorly constructed one destroys credibility. Here is how to do it right.

Select 5-8 primary comparables. Match on four dimensions in order of importance: therapeutic area, development phase, modality, and deal timing (within 3 years). Perfect matches are rare — prioritize TA and phase, then explain adjustments for modality and timing differences.

Show the full range. Include at least one comparable at the high end and one at the low end. Committees distrust comp sets where every transaction supports the proposed valuation — it signals cherry-picking. Present the range honestly, then argue for where the proposed deal should fall within that range.

Normalize for deal structure. Not all “$1B deals” are equal. A deal with $300M upfront and $700M in milestones is very different from one with $100M upfront and $900M in milestones. Present comparables with consistent metrics: upfront, total deal value, upfront ratio, milestone structure, royalty range, and deal type (licensing vs. co-development vs. option).

Explain outliers. If a comparable is significantly above or below the range, explain why. Was it a competitive auction (higher price)? A distressed seller (lower price)? A platform deal vs. single-asset (different structure)? Outlier explanations demonstrate analytical rigor.

Section 3

How to Present rNPV With Scenarios

Risk-adjusted net present value is the standard methodology for biopharma deal valuation. The key to a convincing rNPV presentation is not the base case number — it is the framework around it. Committees approve frameworks, not numbers.

Bear case. Use conservative assumptions: lower market share (25th percentile of comparables), slower uptake, higher attrition rates (published LOA tables + 10%), and compressed pricing. The bear case should still show positive value — if it does not, the deal has insufficient margin of safety.

Base case. Use median assumptions from comparable benchmarks: median market share, median uptake curve, published probability of success by phase, and benchmark pricing. The base case is your primary recommendation.

Bull case. Use optimistic but defensible assumptions: accelerated approval pathway, combination opportunity adding 30-50% to addressable market, best-in-class efficacy scenario. The bull case should be achievable, not theoretical.

Tornado sensitivity chart. Show which 3-4 assumptions drive 80% of the valuation range. Typical high-sensitivity variables include: probability of technical success at current phase, peak revenue market share, pricing assumptions, and time to peak sales. The tornado chart communicates to the committee exactly where the risk lives — and where monitoring should focus post-deal.

Section 4

Common Mistakes That Kill Deals at Committee

Five mistakes cause deal committee rejections or delays more than any other factors. Each is avoidable with proper preparation.

1. Cherry-picked comparables. The number one credibility killer. If the committee discovers that you omitted a directly comparable deal that traded at lower terms, they will question every other number in your presentation. Always present the full range and argue your position within it.

2. Single-scenario valuation. A single rNPV number without sensitivity analysis tells the committee nothing about risk. They cannot evaluate the margin of safety, identify key assumptions to monitor, or define walk-away conditions. Always present bear/base/bull with a tornado chart.

3. Ignoring competitive pipeline risk. Committees will ask “what if a competitor gets there first?” If your presentation does not address this scenario with specific competitive assets and modeled impact on market share, the committee will either reject the deal or add a significant discount that may kill the economics.

4. No walk-away point. Without a clear walk-away point (maximum upfront, minimum milestones, royalty ceiling), the committee has no framework for evaluating counter-offers during negotiation. This leads to repeated committee meetings for every term change, slowing the deal and frustrating the counterparty.

5. Market sizing without bottoms-up validation. Top-down market sizing (incidence x treatment rate x price) overstates addressable markets by 30-50%. Committees expect bottoms-up validation: specific patient segments, realistic treatment sequencing, payer coverage assumptions, and competitive share. Use the Market Sizing engine for validated estimates.

Section 5

Building the Negotiation Playbook

The negotiation playbook is the section most often missing from deal committee presentations — and the one that saves the most time post-approval. A pre-approved playbook gives the BD team clear authority during negotiations, eliminating the cycle of returning to committee for approval on every term change.

Component 1: Walk-Away Economics

Define the maximum upfront payment, total deal value ceiling, and royalty rate boundaries that still deliver positive risk-adjusted returns. The walk-away point should be derived directly from your bear-case rNPV — if terms push below the bear case, the deal no longer has sufficient margin of safety.

Component 2: Trade-Off Matrix

Map the concessions you are willing to make and what you expect in return. Common trade-offs include: higher upfront for lower royalties, milestone restructuring for faster timelines, territory restrictions for reduced upfront, and co-promotion rights for reduced milestones. Present this as a 2x2 matrix so the committee can pre-approve trade-off packages.

Component 3: Competitive Leverage

Document other interested parties, their likely timelines, and what they bring to the table. Even if the counterparty is the preferred partner, the committee needs to know what alternatives exist. Competitive leverage affects every term in the negotiation — parties with alternatives negotiate from strength.

Component 4: Sequencing Strategy

Define which terms to negotiate first and which to hold. The typical sequence is: upfront and total deal value first (establishes the economic framework), then milestone structure and timing, then royalty rates and tiers, and finally governance, territory, and co-development terms. Sequencing prevents early concessions on low-priority terms from constraining high-priority negotiations.

Section 6

Frequently Asked Questions

What should a deal committee presentation include?

Three core elements: comparable transactions (5-8 primary comps showing the deal range), risk-adjusted valuation (bear/base/bull rNPV with sensitivity), and negotiation parameters (walk-away points, trade-off matrix, competitive leverage). Supporting sections include competitive landscape, market sizing, strategic rationale, and partner analysis.

How many comparable transactions should I include?

Five to eight in the main presentation, 15-20 in the appendix. Match on TA, phase, modality, and recency. Include outliers on both ends and explain them. The Deal Report automatically matches comparable transactions from 1,600+ verified deals.

How do I present rNPV to a deal committee?

Always present three scenarios (bear/base/bull) with a tornado sensitivity chart showing which 3-4 assumptions drive 80% of the range. The base case uses median benchmarks; the bear case uses conservative assumptions; the bull case is optimistic but defensible. See our rNPV vs DCF guide for methodology details.

What are common mistakes in deal committee presentations?

Five killers: cherry-picked comparables, single-scenario valuation, ignoring competitive risk, no defined walk-away point, and unvalidated market sizing. Each is avoidable with proper data preparation. The Ambrosia Deal Report addresses all five automatically.

How long does it take to prepare a deal committee presentation?

Traditional preparation takes 2-4 weeks of analyst time for comparable deal research, valuation modeling, and competitive analysis. With the Deal Report ($499), the data foundation is generated in 60 seconds — leaving your team to focus on strategic narrative and internal stakeholder management rather than data compilation.